Work

A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.3080

Authors: Richard D. Kim, Nilofer Saba Azad, Michael Morse, Benjamin R. Tan, Elizabeth Poplin, Melony A. Beatson, Sharon Mavroukakis, Karen Cui, Philip M. Arlen, Muhammad Shaalan Beg

Institutions: Moffitt Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Duke Medical Center, Washington University in St. Louis, Rutgers Cancer Institute, National Cancer Institute, The University of Texas Southwestern Medical Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890337375

Cites:

Cited by:

Related to: 10